✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Patent 8,921,341 protects EPCLUSA and VOSEVI and is included in three NDAs.
Protection for EPCLUSA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and twenty-seven patent family members in thirty-nine countries.
Summary for Patent: 8,921,341
|Abstract:||The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.|
|Inventor(s):||Bacon; Elizabeth M. (Burlingame, CA), Cottell; Jeromy J. (Redwood City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Taylor; James (San Mateo, CA), Tran; Chinh Viet (San Diego, CA), Trejo Martin; Teresa Alejandra (Union City, CA), Yang; Zheng-Yu (Palo Alto, CA), Zipfel; Sheila (San Mateo, CA)|
|Assignee:||Gilead Pharmasset LLC (Foster City, CA)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Argentina||083711||See Plans and Pricing|
|Australia||2011328980||See Plans and Pricing|
|Australia||2012318253||See Plans and Pricing|
|Australia||2015243078||See Plans and Pricing|
|Australia||2017202461||See Plans and Pricing|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|